Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / August 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

GRAIL SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 31, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

GRAIL INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

Biogen

Exelixis

As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors demanding new executives, new boards and new strategies.

Biotech Battlefields: 3 Stocks to Watch Amid Wall Street Turmoil

SAN DIEGO , July 25, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar's suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques, improving patient access to personalized cancer treatment options.

Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options

Illumina (ILMN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Illumina (ILMN) Soars 3.4%: Is Further Upside Left in the Stock?

Advanced Micro Devices

CoStar Group

DexCom

Enphase Energy

Fortinet

Eli Lilly

Monolithic Power Systems

ServiceNow

SolarEdge Technologies

Tesla

Take-Two Interactive Software

As the 2023 stock-market rally continues, this is a good time to look further ahead to see which companies are expected to show the highest growth rates through 2025.

These 13 S&P 500 stocks stand out for expected growth through 2025

LOS ANGELES, CA / ACCESSWIRE / July 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

GRAIL SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

SAN DIEGO , July 18, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2023 following the close of market on Wednesday, August 9, 2023.  On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Charles Dadswell, Interim Chief Executive Officer and General Counsel, and Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

Alliance aims to accelerate therapeutic development and expand the diversity of genomic data through inclusion of more samples from currently underrepresented ancestries SAN DIEGO , July 18, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, in collaboration with Nashville Biosciences, LLC, a leading clinical and genomic data company and wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), today announced the five founding members of the Alliance for Genomic Discovery (AGD). The multiyear agreement aims to accelerate development of therapeutics through large-scale genomics and the establishment of a preeminent clinical genomic resource.

The Alliance for Genomic Discovery announces founding biopharma members: AbbVie, Amgen, AstraZeneca, Bayer, and Merck

LOS ANGELES, CA / ACCESSWIRE / July 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

LONG-TERM GRAIL SHAREHOLDERS ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

Alibaba

Shady Business: 3 Well-Known Stocks That Deserve to Be on Your Blacklist

LOS ANGELES, CA / ACCESSWIRE / July 17, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

GRAIL/ILLUMINA SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

GRAIL/ILLUMINA INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Illumina, Inc. ("Illumina" or "the Company") (NASDAQ:ILMN) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Stratasys board breached its fiduciary duties to shareholders.

INVESTOR ACTION NOTICE FOR LONG-TERM SHAREHOLDERS: The Schall Law Firm Announces it is Investigating Claims Against Illumina, Inc. and Encourages Investors with Losses to Contact the Firm

Illumina's (ILMN) DRAGEN v4.2 is expected to improve the identification of genetic disease causes, drug discovery and population genomics.

Illumina's (ILMN) Latest Launch to Boost Genomics Analysis

Illumina, Inc, a genetic testing company, was fined a record 432-million-euro (US$476 million) by the European Union (EU) on Wednesday for closing its takeover of cancer test maker Grail before securing EU antitrust approval, Reuters reported. The media outlet also noted the European Commission said the size of the fine, amounting to 10% of Illumina's global revenue and the maximum allowed under EU merger rules for such infringements, underscored the seriousness of the offence and aimed to deter such conduct.

Illumina receives record US$476M fine from EU for closing Grail deal without approval

The European Commission fined biotech firm Illumina 432 million euros ($476 million) for closing its acquisition of Grail without the commission's approval, in the Commission's largest merger regulation fine yet.﻿

EU Fines Illumina Record $476 Million for Closing Grail Deal Without Approval

The European Commission says the gene-sequencing company completed its acquisition of Grail, a cancer test developer, before receiving the appropriate approvals.

Illumina to Appeal EU Fine for Closing Grail Acquisition Early

The record antitrust fine from the EU comes months after the FTC ordered the company to divest its $7.1 billion acquisition of Grail.

Illumina Fined $476 Million For Acquiring Cancer Test Maker Grail Without EU Approval

EU antitrust regualators on Wednesday fined Illumina a record 432 million euros ($476.19 million) for closing its takeover of Grail before securing EU antitrust approval.

EU regulators fine Illumina $476 mln for closing Grail deal without green light

The European Commission last year blocked Illumina's $7.1 billion acquisition of Grail over concerns it would stifle innovation and consumer choice.

Illumina hit with record fine for closing Grail deal without EU regulatory approval

The European Union's antitrust watchdog fined the company with the maximum allowable amount for wrapping up its acquisition of the cancer-test developer while the agency was still reviewing it.

Illumina Fined More Than $400 Million in Europe for Closing Grail Deal Early

2023 marks five years of industry-leading DRAGEN software offered by Illumina SAN DIEGO , July 11, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of the latest version of DRAGEN™ software for analysis of next-generation sequencing data. DRAGEN 4.2 expands award-winning accuracy combined with its renowned flexibility and scalability to enable efficient workflows and extract meaningful insights from genomic data.

Illumina DRAGEN™ 4.2 delivers most accurate and comprehensive coverage of the genome, powering greater applications and discovery

While this may not happen anytime soon, ILMN stock looks attractive from a valuation perspective and can see higher levels.

Will Illumina Stock Rebound After A 65% Decline In The Ongoing Inflation Shock?

Illumina Inc. ILMN, -4.85% disclosed Monday that it has begun laying off workers, as the DNA-sequencing company looks to cut costs amid a withering fight with activist investor Carl Icahn. In a filing with the Securities and Exchange Commission, Illumina stated that it began laying off workers on June 21, and expects to continue the cuts into the third quarter.

News for Illumina Stock (ILMN)